Paul T. Henderson, Ph.D.

Clinical/Research Interests

Mechanisms of cellular response to oxidative stress, drug and carcinogen metabolism, pharmacokinetics assay development, mass spectrometry, HPLC. Dr. Henderson is pursuing the development of advanced diagnostics with the goal of predicting patient response to cancer drugs prior to initiation of toxic chemotherapy. The diagnostics development is enabled by accelerator mass spectrometry (AMS), an ultrasensitive technology for detecting rare isotopes such as radiocarbon and tritium in biological samples. AMS is also useful for measuring pharmacokinetics of small drug doses in humans, which Dr. Henderson is applying to drug development and drug formulation studies. Another project involves the incorporation of hydrophobic drugs and membrane proteins into nanoparticles made of apolipoproteins and phospholipids called nanolipoproitein particles (NLPs). NLPs closely mimic the cellular membrane bilayer, and render hydrophobic molecules water soluble. Dr. Henderson is using NLPs for drug delivery and protein biochemistry studies that are related to breast cancer research.

Title:

Assistant Adjunct Professor

Specialty:

Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center

Education:

Georgia Institute of Technology
Atlanta, Georgia
Ph.D. 1999

University of Florida
Gainesville, Florida
B.S. 1992

Professional Memberships:

American Association for Advancement of Science
American Association for Cancer Research
American Chemical Society
Environmental Mutagen Society

Select Recent Publications:

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

Gao T, Blanchette CD, He W, Bourguet F, Ly S, Katzen F, Kudlicki WA, Henderson PT, Laurence TA, Huser T, Coleman MA. Characterizing diffusion dynamics of a membrane protein associated with nanolipoproteins using fluorescence correlation spectroscopy. Protein Sci. 2011 Feb;20(2):437-47. doi: 10.1002/pro.577.

Coldwell K, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of adriamycin-DNA adducts by accelerator mass spectrometry. Methods Mol Biol. 2010;613:103-18.

Henderson PT, Evans MD, Cooke MS. Salvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA. Mutat Res. 2010 Nov 28;703(1):11-7. Epub 2010 Sep 15. Review.

Hah SS, Henderson PT, Turteltaub KW. Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. Epub 2010 Mar 7.

Henderson PT, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis. 2010 Mar;2(3):373-6.

Baker SE, Hopkins RC, Blanchette CD, Walsworth VL, Sumbad R, Fischer NO, Kuhn EA, Coleman M, Chromy BA, Létant SE, Hoeprich PD, Adams MW, Henderson PT. Hydrogen production by a hyperthermophilic membrane-bound hydrogenase in water-soluble nanolipoprotein particles. J Am Chem Soc. 2009 Jun 10;131(22):7508-9.

Cooke MS, Henderson PT, Evans MD. Sources of extracellular, oxidatively-modified DNA lesions: implications for their measurement in urine. J Clin Biochem Nutr. 2009 Nov;45(3):255-70. Epub 2009 Oct 28.

Hah SS, Henderson PT, Turteltaub KW. Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci. 2009 Jun 17;16:54. Review. Erratum in: J Biomed Sci. 2009;16:111.